THE ROLE OF AT-HOME CONSUMER DIAGNOSTICS INCREASES Saliva-based home pregnancy test arrives at Australian pharmacies
With
Dr Anita Sharma, GP
Platinum Medical Centre,
Brisbane
Michael Cima, CEO & Director
CC Supplies,
Byron Bay
SEGMENT
Filmed in Brisbane | March 2026
Since the COVID-19 pandemic, consumer diagnostics have rapidly advanced, with more people becoming aware of and comfortable using at-home testing. These tests provide greater convenience, control, and empowerment, allowing individuals to monitor their health without immediately consulting a healthcare professional. Recently, this shift has been particularly impactful in areas such as pregnancy testing, where saliva-based diagnostics now enable earlier and more accessible detection.
According to Dr Anita Sharma, a Brisbane based GP at Platinum Medical Centre, traditional medical testing still plays an important role. Situations such as unclear symptoms, early-stage conditions with low detectable markers, or practical limitations—like insufficient saliva samples—may require confirmation through standard clinical methods. Additionally, many patients seek reassurance from healthcare professionals even after receiving positive at-home results, particularly when further care planning is needed.
As a result, the role of healthcare practitioners is evolving, according to Dr Sharma. Rather than acting solely as gatekeepers to testing, they are increasingly becoming interpreters and validators of patient-led diagnostics. According to Dr Sharma, GPs now focus more on guiding care, confirming results, and supporting patient decisions. To do this effectively, Dr Sharma states GPs must stay informed through continuous education, engagement with peers, and awareness of emerging diagnostic technologies and trends in healthcare.
Australian Health Journal also spoke with Michael Cima, CEO and Director of CC Supplies about the accessibility of consumer diagnostics and where women are able to choose how to test, have improved access and opt for privacy.
Source: Adapted from transcript
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
-
National Cancer Plan activates Australian Comprehensive Cancer Network
The landscape of cancer care in Australia is set to transform with the Australian Government launch in May 2024 of the Australian Comprehensive Cancer Network (ACCN) at the Innovations Showcase event, hosted by Cancer Australia in Sydney, Australia.
The ACCN is a nationally integrated system of cancer care, aimed at enhancing patient experiences and outcomes through coordinated and equitable access, by linking to comprehensive cancer services across Australia. Anchored by Comprehensive Cancer Centres (CCCs), the ACCN strives to deliver evidence-driven prevention, diagnosis, treatment, and support to all Australians affected by cancer.
-
New clinical research entity first to operate across both Australia and New Zealand
Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing, until now.
